| Patient | Mildred Ella Didrikson Zaharias |
|---|---|
| Date of birth | 1984-06-26 |
| Identifiers | MRN HR-ML038-SYN; SSN (made up) 000-38-4471 |
| Document date | 2026-03-30 |
| Author | Rosalind Vasquez-Thornbury, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: biopsy and staging results, the tumor board plan, and the oncology and surgical consultations. [S]
Ms. Didrikson Zaharias returns two weeks after her first visit. Colonoscopy three days after that visit found an ulcerated mass in the lower rectum, from 4 to 9 cm from the anal verge, and nothing else in the colon; the biopsies show adenocarcinoma, and the tumor has lost the mismatch repair proteins MSH2 and MSH6 and is microsatellite instability high. Rectal-protocol MRI shows a tumor whose lower edge is about 1 cm above the anorectal junction, growing just through the bowel wall, with two suspicious lymph nodes and a clear mesorectal fascia (cT3bN1). CT of the chest, abdomen and pelvis shows no spread. The tumor board met three days ago. She was seen today by Dr. Albright-Nakamura and by the colorectal surgeon, who explained that surgery for a tumor this low would most likely mean removing the rectum and anus with a permanent colostomy. She still passes some bright red blood most days, less than before, and feels tired on the back nine. Her first question was whether she would need a bag; her second was whether she could keep playing. [S]
| Element | Detail |
|---|---|
| Diagnosis | Low rectal adenocarcinoma, mismatch repair deficient (loss of MSH2 and MSH6), cT3bN1M0, stage IIIB |
| Procedures since the first visit | Colonoscopy with biopsy; rectal-protocol MRI of the pelvis; CT of the chest, abdomen and pelvis; tumor board |
| Tumor board | Dostarlimab every three weeks for six months, restaging about every three months, and watch-and-wait if the response is complete; chemoradiation and surgery in reserve |
| Symptoms | Less bleeding; still some urgency; tired late in a round |
| Her questions | Whether she will need a bag; whether she can keep competing; what the genetic test means for her brothers and sisters |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired late in a round; weight 62.6 kg, steady; no fever |
| Gastrointestinal | Positive | Bright red blood on most days, less than before; urgency; narrow stools |
| Genitourinary | Positive | Pain during sex and spotting afterwards; no urinary symptoms |
| Cardiovascular | Negative | No palpitations, fainting or leg swelling |
| Musculoskeletal | Negative | No back or pelvic pain |
| Psychiatric | Positive | Frightened by the word cancer and determined; PHQ-9 6, GAD-7 7; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning | One tablet every other morning | Oral route | 2026-03-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-30 | Body height | 168 | cm | S |
| 2026-03-30 | Body weight | 62.6 | kg | S |
| 2026-03-30 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-03-30 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-03-30 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-30 | Heart rate | 80 | /min | S |
| 2026-03-30 | Respiratory rate | 14 | /min | S |
| 2026-03-30 | Body temperature | 36.6 | Cel | S |
| 2026-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-30 | Hemoglobin [Mass/volume] in Blood | 11.1 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-03-30 | Leukocytes [#/volume] in Blood by Automated count | 6.5 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-30 | Platelets [#/volume] in Blood by Automated count | 405 | 10*3/uL | 150-400 10*3/uL | High | S |
| 2026-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-30 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 | U/L | 7-35 U/L | Normal | S |
| 2026-03-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 2026-03-30 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-03-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-03-30 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Fit, tanned, composed; weight 62.6 kg; blood pressure 116/72, pulse 80 |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Rectal | With her agreement and a chaperone: firm, ulcerated, partly mobile mass on the posterior and left wall, lower edge about 4 to 5 cm from the anal verge; sphincter tone normal; blood on the glove |
| Psychiatric | Direct and focused; asks exact questions about her game and about a colostomy |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | K62.5 | S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season. |
| Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | C20 | S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis and mismatch repair testing | Before treatment; mismatch repair testing for every colorectal cancer | Up to date | Adenocarcinoma, moderately differentiated; loss of MSH2 and MSH6 on immunohistochemistry; microsatellite instability high |
| Imaging | Rectal-protocol MRI of the pelvis | At diagnosis, before any treatment | Up to date | cT3b, two suspicious mesorectal nodes (cN1), mesorectal fascia clear by 6 mm, no extramural venous invasion, lower edge about 1 cm above the anorectal junction |
| Imaging | CT of the chest, abdomen and pelvis | At diagnosis | Up to date | No metastases |
| Referral | Multidisciplinary tumor board | Before treatment for every rectal cancer | Up to date | Three days ago: dostarlimab, restaging, watch-and-wait if complete response |
| Referral | Colorectal surgery consultation | Before treatment of every rectal cancer | Completed today | Seen today: surgery now would most likely be abdominoperineal resection with a permanent colostomy; surgery kept in reserve for an incomplete response or regrowth |
| Referral | Wound-ostomy nursing: stoma site marking and teaching | Before any operation that may create a stoma | Not indicated | No operation planned; to be arranged at once if surgery becomes necessary |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Up to date | 5.8 ng/mL at the first visit; next with restaging |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Lower edge about 4 to 5 cm from the anal verge; sphincter tone normal |
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Hemoglobin 11.1 g/dL, white cells 6.5, platelets 405 |
| Laboratory | Kidney and liver function and glucose | At baseline and before each dose of PD-1 blockade | Completed today | Creatinine 0.76 mg/dL, eGFR 101; ALT 17 U/L, AST 20 U/L; glucose 90 mg/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | Baseline TSH 1.9 mIU/L, free T4 1.2 ng/dL |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
| Laboratory | Pregnancy test | Before treatment | Completed today | Urine pregnancy test negative |
| Medication safety | Contraception during PD-1 blockade | Throughout treatment and for four months after the last dose | Up to date | Levonorgestrel intrauterine device in place |
| Laboratory | Germline multigene panel | For every colorectal cancer diagnosed under 50 and every mismatch repair-deficient tumor | Ordered | Sent today after counseling |
| Referral | Genetic counseling | Before germline testing | Completed today | Pedigree as she knows it; she knows of no relative with a Lynch-associated cancer; consent for testing |
| Self-management | Teaching about immune-related adverse events | Before the first dose | Completed today | Written guide and 24-hour line: report diarrhea, blood in the stool, rash, cough, breathlessness, unusual tiredness, headache or thirst |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 6 (item 9 scored 0), GAD-7 7 |
| Self-management | Sexual health and body image | At diagnosis and through treatment | Completed today | Pain and spotting after sex explained by the tumor; told they should settle as it responds; a lubricant meanwhile |
| Self-management | Physical activity and sport | Each visit | Completed today | Encouraged to keep playing and training as she feels able; no restriction from dostarlimab |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)
Follow-up: Dostarlimab cycle 1 next week. Primary care review at cycle 2. Call at once for heavy bleeding, fainting, diarrhea, rash, cough or breathlessness. Next scheduled visit 2026-04-27: day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golf. [S]